Search academic texts

Information × Registration Number 0218U001556, 0117U000406 , R & D reports Title Develop methods chemoradiotherapy patients with secondary (metastatic) cancer of the vagina using various sources of radiation popup.stage_title Head Ivankova Valentina Stepanovna, Доктор медичних наук Registration Date 22-02-2018 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 The subject of the study - 33 patients with secondary (metastatic) cancer of the vagina. The purpose of the work is to increase the effectiveness of radiotherapy for patients with secondary (metastatic) vaginal cancer by using optimal planning, conformal irradiation, high-energy brachytherapy (192Ir, 60Co) and cytostatic drugs. The program of quality control of the linear accelerator of electrons "Clinac 2100 CD" for conformal radiotherapy (KPT) of patients with secondary (metastatic) vaginal cancer has been developed; defined stages and sequencing of topometric preparation and planning of conformal irradiation and contact fusion with sources 192Ir and 60Co of high activity (HDR) for patients with secondary (metastatic) vaginal cancer; developed methods of chemo-ray therapy (CRT) for patients with secondary (metastatic) cancer of the vagina using cytostatic drugs (fluorouracil, cisplatin) as radiomodifiers during conformal PT and HDR 192Ir-brachytherapy under different regimens and HDR 60Co-brachytherapy. The study included 33 patients with secondary (metastatic) vaginal cancer who were undergoing CPT at stage I of the combined radiation therapy (PDT): a single focal dose (ORD) of 2.0 Gy to a total focal dose (SOD) was administered to the small pelvis area 30 -40 Gy, taking into account the dose of irradiation, summed up with previous radiation therapy. At stage II of the PTC course, all groups were subjected to high-energy (HDR) intracavitary brachytherapy (BT) with sources 192Ir (GammaMed plus IX) or 60Со (GyneSource device). Depending on the source and mode of exposure, the patients are divided into two main and control groups. The first main group was 11 patients with secondary (metastatic) vaginal cancer, which HDR BT conducted 192Ir sources according to the regimen: ROD = 3 Gy x 3p / week. In the II main group included 10 patients with secondary (metastatic) cancer of the vagina, which HDR BT conducted sources 192Ir by regimen: ROD = 5 Gy x 2p / week. The control group consisted of 12 patients with secondary (metastatic) cancer of the vagina, which HDR BT was operated by sources 60Co according to the regimen: ROD = 5 Gy x 2 g / week. During the course of PPT, patients with major groups received fluorouracil orally 400 mg x 2 times a day and cisplatin 50 mg 1 time per week intravenously drops 4-6, to DM 200-300 mg. The analysis of direct efficacy and toxicity of the developed methods of radiotherapy for patients with secondary (metastatic) vaginal cancer testifies to their effectiveness and absence of excessive toxicity (above II degree). It has been established that the use of 192Ir source for HDR BP in developed regimens in patients with major groups somewhat contributes to the reduction of toxic manifestations of CRT compared to the control group (HDR BT with sources of 60Co) and does not reduce direct efficacy treatment. Product Description popup.authors Іванкова Валентина Степанівна Бакай Ольга Олексіївна Барановська Лідія Михайловна Галяс Оксана Вікторівна Палій Максім Ігорович Скоморохова Тетяна Володимирівна Хруленко Тетяна Валерівна popup.nrat_date 2020-04-02 Close